Resorbable and biocompatible fibre glass compositions and their uses

Patent metadata

Field	Value
Publication number	US-9381277-B2
Application number	US-201414245071-A
Country	US
Kind code	B2
Filing date	Apr 4, 2014
Priority date	Apr 23, 2009
Publication date	Jul 5, 2016
Grant date	Jul 5, 2016

Abstract

Biocompatible and resorbable melt derived glass compositions which include: SiO 2 60-70 weight-%, Na 2 O 5-20 weight-%, CaO 5-25 weight-%, MgO 0-10 weight-%, P 2 O 5 0.5-3.0 weight-%, B 2 O 3 0-15 weight-%, Al 2 O 3 0-5 weight-%, and which contain less than 0.05 weight-% potassium. Biocompatible and resorbable glass fibers manufactured from these glass compositions, medical devices containing fibers of the invention, the use of these compositions for the manufacture of glass fiber and the use of the fibers for the manufacture of medical devices are also disclosed.

First claim

The invention claimed is:

1. An implant comprising a biocompatible and resorbable glass fibre manufactured from a biocompatible and resorbable melt derived glass composition comprising:

SiO 2
60-70
weight-%,

Na 2 O
5-20
weight-%,

CaO
5-25
weight-%,

MgO
0-10
weight-%,

P 2 O 5
0.5-3.0
weight-%,

B 2 O 3
0-15
weight-%,

Al 2 O 3
0-5
weight-% and

comprising less than 0.05 weight-% potassium, said resorbable glass fiber having a full resorption time in vitro of 3-100 months when calculated using a resorption rate determined by dissolution in simulated body fluid under in sink conditions at +37° C. using a linear portion of a resorption curve.

2. The implant according to claim 1 , wherein said glass fiber comprises chopped and/or continuous glass fibre.

3. The implant according to claim 1 wherein said implant is selected from the group consisting of a joint implant, an internal/external fixation device, a stent, a pin, a nail, a screw, a spike, a stud, a plate, and a device for supporting tissue or bone healing and/or regeneration.

4. The implant according to claim 1 , wherein the amount of biocompatible and resorbable glass fibre is >10 volume-% of the total volume of the fibers of said implant.

5. The implant according to claim 1 wherein the fibers are embedded in a continuous polymer matrix.

6. The implant according to claim 5 wherein the polymer matrix comprises at least one polymer selected from the group consisting of polyglycolide (PGA); copolymers of glycolide; polylactides (PLA); stereocopolymers of PLA; copolymers of PLA; terpolymers of PLA; polydepsipeptides; unsymmetrically 3,6-substituted poly-1,4-dioxane-2,5-diones; polyhydroxyalkanoates; PHB/b-hydroxyvalerate copolymers (PHB/PHV); poly-b-hydroxypropionate (PHPA); poly-p-dioxanone (PDS); poly-d-valerolactone; poly-ε-caprolactone; methylmethacrylate-N-vinyl pyrrolidone copolymers; polyesteramides; polyesters of oxalic acid; polydihydropyrans; polyalkyl-2-cyanoacrylates; polyurethanes (PU); polyvinyl-alcohol (PVA); polypeptides; poly-b-malic acid (PMLA); poly-b-alkanoic acids; polycarbonates; polyorthoesters; polyphosphates; poly(ester anhydrides) and mixtures or thermosets thereof.

7. The implant according to claim 1 wherein said melt derived glass composition comprises less than 0.03 weight-% potassium.

8. The implant according to claim 1 wherein said melt derived glass composition comprises

SiO 2
62-68
weight-%,

Na 2 O
10-15
weight-%,

CaO
8-20
weight-%,

MgO
0-10
weight-%,

P 2 O 5
0.5-3
weight-%,

B 2 O 3
0-4
weight-% and

Al 2 O 3
0-2.5
weight-%.

9. The implant of claim 1 wherein the thickness of the fibre is <300 μm.

10. The implant of claim 1 wherein the tensile strength of the fibre is 0.7-3 GPa.

11. The implant according to claim 6 wherein the stereocopolymers of PLA are selected from the group consisting of poly-L-lactide (PLLA), poly-DL-lactide (PDLLA) and L-lactide/DL-lactide copolymers.

12. The implant according to claim 6 wherein the PLA copolymers are selected from the group consisting of lactide/tetramethylglycolide copolymers, lactide/trimethylene carbonate copolymers, lactide/d-valerolactone copolymers and lactide/ε-caprolactone copolymers.

13. The implant according to claim 6 wherein the PLA terpolymers are selected from the group consisting of lactide/glycolide/trimethylene carbonate terpolymers, lactide/glycolide/ε-caprolactone terpolymers, and PLA/polyethylene oxide copolymers.

14. The implant according to claim 1 , wherein said resorption time is 5-30 months.

Assignees

• Purac Biochem Bv

Inventors

• Lehtonen Timo
• Tuominen Jukka
• Ollila Fredrik

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61L27/58

  Materials at least partially resorbable by the body · CPC title

• C03C2201/10

  containing boron (C03C2201/14 takes precedence) · CPC title

• A61L31/026 Primary

  Ceramic or ceramic-like structures, e.g. glasses · CPC title

• C03C4/0007

  for biologically-compatible glass · CPC title